JP2014513952A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513952A5
JP2014513952A5 JP2014506579A JP2014506579A JP2014513952A5 JP 2014513952 A5 JP2014513952 A5 JP 2014513952A5 JP 2014506579 A JP2014506579 A JP 2014506579A JP 2014506579 A JP2014506579 A JP 2014506579A JP 2014513952 A5 JP2014513952 A5 JP 2014513952A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acids
kda
seq
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014506579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513952A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/034479 external-priority patent/WO2012145644A1/en
Publication of JP2014513952A publication Critical patent/JP2014513952A/ja
Publication of JP2014513952A5 publication Critical patent/JP2014513952A5/ja
Pending legal-status Critical Current

Links

JP2014506579A 2011-04-22 2012-04-20 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ Pending JP2014513952A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22
US61/478,336 2011-04-22
PCT/US2012/034479 WO2012145644A1 (en) 2011-04-22 2012-04-20 Modified acid alpha glucosidase with accelerated processing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016185075A Division JP2017035091A (ja) 2011-04-22 2016-09-23 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ

Publications (2)

Publication Number Publication Date
JP2014513952A JP2014513952A (ja) 2014-06-19
JP2014513952A5 true JP2014513952A5 (cg-RX-API-DMAC7.html) 2015-05-28

Family

ID=46000406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014506579A Pending JP2014513952A (ja) 2011-04-22 2012-04-20 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ
JP2016185075A Pending JP2017035091A (ja) 2011-04-22 2016-09-23 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016185075A Pending JP2017035091A (ja) 2011-04-22 2016-09-23 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ

Country Status (24)

Country Link
US (1) US20140186326A1 (cg-RX-API-DMAC7.html)
EP (1) EP2699676A1 (cg-RX-API-DMAC7.html)
JP (2) JP2014513952A (cg-RX-API-DMAC7.html)
KR (1) KR20140037082A (cg-RX-API-DMAC7.html)
CN (1) CN103797115A (cg-RX-API-DMAC7.html)
AU (1) AU2012245280A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013026976A2 (cg-RX-API-DMAC7.html)
CA (1) CA2833371A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013003010A1 (cg-RX-API-DMAC7.html)
CO (1) CO6811810A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130555A (cg-RX-API-DMAC7.html)
EC (1) ECSP13013036A (cg-RX-API-DMAC7.html)
GT (1) GT201300252A (cg-RX-API-DMAC7.html)
IL (1) IL228871A0 (cg-RX-API-DMAC7.html)
MA (1) MA35125B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013012345A (cg-RX-API-DMAC7.html)
NI (1) NI201300110A (cg-RX-API-DMAC7.html)
PE (1) PE20140617A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502149A1 (cg-RX-API-DMAC7.html)
RU (1) RU2013151875A (cg-RX-API-DMAC7.html)
SG (2) SG194486A1 (cg-RX-API-DMAC7.html)
TN (1) TN2013000427A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012145644A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307696B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
CA2961762C (en) 2014-09-30 2024-03-05 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
JP2018538008A (ja) 2015-11-06 2018-12-27 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム酵素の取り込みを中和する抗体または他の因子の検出のための細胞ベースアッセイ
MY198085A (en) * 2015-12-30 2023-07-31 Amicus Therapeutics Inc Augmented acid alpha-glucosidase for the treatment of pompe disease
US10227577B2 (en) * 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
AU2017322376B2 (en) 2016-09-12 2023-08-17 Association Institut De Myologie Acid-alpha glucosidase variants and uses thereof
HRP20230576T1 (hr) 2017-05-15 2023-09-01 Amicus Therapeutics, Inc. Rekombinantna ljudska kisela alfa-glukozidaza
MY198804A (en) 2017-06-07 2023-09-28 Regeneron Pharma Compositions and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
BR112020016005A2 (pt) 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio
CN112135624B (zh) 2018-05-17 2024-07-19 瑞泽恩制药公司 抗cd63抗体、缀合物和其用途
US20220331408A1 (en) 2019-07-09 2022-10-20 Genethon Treatment of glycogen storage disease (gsd)
AU2020388634A1 (en) * 2019-11-19 2022-06-23 AskBio Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating Pompe disease and lysosomal disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
WO2000009153A1 (en) 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
EP2020438B1 (en) 1998-12-07 2018-04-11 Genzyme Corporation Treatment of pompe's disease
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
BR122015016313B8 (pt) 2001-07-16 2021-05-25 Genzyme Corp composto semelhante à ceramida e método de preparar um composto
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
ES2371913T3 (es) * 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
US7423135B2 (en) 2003-06-24 2008-09-09 Genzyme Corporation β-actin and rpS21 promoters and uses thereof
AU2005212435B2 (en) 2004-02-10 2010-09-09 Biomarin Pharmaceutical Inc. Acid alpha-glucosidase and fragments thereof
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
HUE044381T2 (hu) 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
US8466340B2 (en) * 2009-02-18 2013-06-18 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2014513952A5 (cg-RX-API-DMAC7.html)
RU2013151875A (ru) Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
JP2012095641A5 (cg-RX-API-DMAC7.html)
GB201018518D0 (en) Novel endolysin
JP2018520646A5 (cg-RX-API-DMAC7.html)
NZ701881A (en) Vaccines for hsv-2
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
NZ595063A (en) Polypeptides from neisseria meningitidis
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
JP2008530245A5 (cg-RX-API-DMAC7.html)
IN2014DN05670A (cg-RX-API-DMAC7.html)
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
MX336412B (es) Nuevos analogos de glucagon.
JPWO2019156137A5 (cg-RX-API-DMAC7.html)
JP2015508771A5 (cg-RX-API-DMAC7.html)
JP2015514132A5 (cg-RX-API-DMAC7.html)
JP2019533722A5 (cg-RX-API-DMAC7.html)
EA201790178A1 (ru) Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
EA201170917A1 (ru) Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
JP2018537089A5 (cg-RX-API-DMAC7.html)
MY190257A (en) Optimised subcutaneous therapeutic agents
JP2014529399A5 (cg-RX-API-DMAC7.html)
JP2015514115A5 (cg-RX-API-DMAC7.html)